Welcome to our dedicated page for Glaukos Corporation news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation stock.
Glaukos Corporation (NYSE: GKOS) is a prominent ophthalmic medical technology company specializing in breakthrough products and procedures aimed at transforming the treatment of glaucoma. As one of the leading causes of blindness globally, glaucoma demands innovative solutions, and Glaukos has pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize traditional management paradigms.
The company's flagship product, the iStent Trabecular Micro-Bypass Stent, launched in the United States in 2012, is celebrated for being the smallest medical device ever approved by the FDA, measuring a mere 1.0 mm long and 0.33 mm wide. This device is designed to reduce intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma when used in conjunction with cataract surgery.
Building on the success of the iStent, Glaukos is developing a comprehensive and proprietary portfolio of injectable micro-scale therapies targeting the entire spectrum of glaucoma disease states and progression. The pipeline includes the iStent SA Trabecular Micro-Bypass System, a two-stent product with a different auto-injection inserter for standalone procedures.
In June 2015, Glaukos successfully completed its initial public offering, and its shares are now publicly traded on the New York Stock Exchange. The company continues to innovate and expand its product offerings, maintaining its position as a leader in the ophthalmic medical technology field.
- Recent achievements include the expansion of their product pipeline and the ongoing development of next-generation MIGS devices.
- Current projects focus on enhancing the efficacy and accessibility of glaucoma treatments worldwide.
- Partnerships with leading ophthalmic institutions and research organizations fuel Glaukos' mission to improve patient outcomes.
Glaukos Corporation remains committed to transforming glaucoma treatment through technological innovation and strategic growth.
Glaukos Corporation (NYSE: GKOS), an innovative company specializing in ophthalmic medical technology, is set to release its first quarter 2023 financial results after the market closes on May 3, 2023. Following the release, management will conduct a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Interested parties can access the webcast via Glaukos' investor relations website. The company is recognized for developing Micro-Invasive Glaucoma Surgery (MIGS) devices and aims to enhance treatment options for glaucoma, corneal disorders, and retinal diseases through continuous innovation.
Glaukos Corporation (NYSE: GKOS) announced the submission of its New Drug Application (NDA) for iDose TR to the U.S. FDA. This micro-invasive implant aims to deliver therapeutic levels of travoprost, improving patient compliance and reducing side effects of traditional glaucoma treatments. The NDA includes data from two successful Phase 3 trials confirming efficacy and safety over 12 months. CEO Thomas Burns highlighted this submission as a significant milestone, emphasizing the potential of iDose TR as a transformative therapy for glaucoma patients. The company aims to work closely with the FDA during the review process.
Glaukos Corporation (NYSE: GKOS) reported Q4 2022 net sales of $71.2 million, a 3% decline from Q4 2021. Glaucoma and Corneal Health net sales were $52.9 million and $18.3 million, respectively. Gross margin was approximately 76%, down from 77% in the previous year. SG&A expenses rose by 9% to $51.9 million, while R&D expenses surged 34% to $35.8 million. The net loss was $31.5 million, or ($0.66) per diluted share. For full year 2022, net sales totaled $282.9 million, a 4% decline year-over-year. The company provided 2023 net sales guidance of $290 million to $295 million, anticipating challenges from the macroeconomic environment.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will participate in the Citi Healthcare Conference on March 1, 2023, at 1:15 p.m. ET, in New York City. The event will include a live and archived webcast accessible on the company's Investors website. Glaukos specializes in developing innovative therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since its initial commercial launch in 2012. The company aims to enhance standard care through its diverse platforms for medical device and pharmaceutical innovations.
Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2022 financial results after market close on
Investors can access the live webcast via Glaukos' investor relations website.
FAQ
What is the current stock price of Glaukos Corporation (GKOS)?
What is the market cap of Glaukos Corporation (GKOS)?
What is Glaukos Corporation?
What is the iStent Trabecular Micro-Bypass Stent?
When did Glaukos go public?
What is MIGS?
What is the iStent SA?
What recent achievements has Glaukos made?
What is the significance of Glaukos' products?
Who are Glaukos' partners?
What is Glaukos' mission?
How does Glaukos continue to innovate?
